Compare HFBL & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HFBL | KPTI |
|---|---|---|
| Founded | 1924 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.6M | 94.6M |
| IPO Year | N/A | 2013 |
| Metric | HFBL | KPTI |
|---|---|---|
| Price | $18.00 | $6.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $22.17 |
| AVG Volume (30 Days) | 2.9K | ★ 165.8K |
| Earning Date | 01-29-2026 | 11-03-2025 |
| Dividend Yield | ★ 2.98% | N/A |
| EPS Growth | ★ 35.20 | N/A |
| EPS | ★ 1.47 | N/A |
| Revenue | $21,720,000.00 | ★ $142,530,000.00 |
| Revenue This Year | N/A | $3.82 |
| Revenue Next Year | N/A | $3.18 |
| P/E Ratio | $12.26 | ★ N/A |
| Revenue Growth | ★ 10.10 | N/A |
| 52 Week Low | $12.31 | $3.51 |
| 52 Week High | $19.20 | $12.45 |
| Indicator | HFBL | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 73.91 | 66.79 |
| Support Level | $15.90 | $5.70 |
| Resistance Level | $19.20 | $6.05 |
| Average True Range (ATR) | 0.29 | 0.45 |
| MACD | 0.19 | 0.16 |
| Stochastic Oscillator | 69.62 | 75.69 |
Home Federal Bancorp Inc of louisiana operates as a bank holding company. It is a federally chartered stock savings bank, which provides financial services to individuals, corporate entities, and other organizations. Its core activities consist of attracting deposits from the general public and using those funds to originate loans to the residential, commercial and multi-family segments. The company also invests securities held-to-maturity and securities available for sale.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.